Results 241 to 250 of about 46,091 (305)

Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial

Allergy, Volume 81, Issue 6, Page 2123-2132, June 2026.
The RHAPSODY multinational study investigated 26 months of continuous treatment with 5‐grass‐pollen sublingual SLIT drops in adults with moderate‐to‐severe grass‐pollen‐induced allergic rhinoconjunctivitis. The primary efficacy endpoint (the average daily total combined score) showed statistically significant differences in favour of the active ...
Alain Didier, Ruta Gronskyte Juhl, Terrie Dalgaard, Antoine Chartier, Philippe Devillier   +4 more
wiley   +1 more source

Spontaneously Resolving Pancreatic IgG4-Related Disease Representing With Systemic Involvement and Membranous Nephropathy. [PDF]

Kidney Med
Raza IGA, Smith SW, Chanouzas D.
europepmc   +1 more source

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side

Allergy, Volume 81, Issue 6, Page 1985-2000, June 2026.
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm, Mohammed Zghaebi, Bita Hambrecht, Tanja Kalic, Christopher C. Udoye, Rudolf Manz, Barbara Bohle, Katarzyna M. Sitnik, Julia Eckl‐Dorna, Heimo Breiteneder   +9 more
wiley   +1 more source

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis. [PDF]

Front Immunol
Gelissen LMY, van den Berg SPH, Toorop AA, Wijburg MT, Tallantyre EC, Derksen NIL, Loeff FC, Killestein J, Rispens T, van Kempen ZLE, NEXT-MS study group .   +10 more
europepmc   +1 more source

A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults

Allergy, Volume 81, Issue 6, Page 2079-2088, June 2026.
This study evaluated safety and tolerability of birch pollen SCIT during dose escalation with a new One‐Strength regimen (3 injections, Strength B) compared to the Standard regimen (7 injections, Strengths A and B) in patients aged 5–65 years. Safety and tolerability were comparable between the two regimens in adults, adolescents, and adolescents, as ...
Marek Jutel, Ludger Klimek, Michael Gerstlauer, Dana Troyke, Kristina Duwensee, Christian Vogelberg   +5 more
wiley   +1 more source

IgG4-sclerosing cholangitis masquerading as cholangiocarcinoma: a case report of an unresolved preoperative diagnosis. [PDF]

Front Immunol
Liu YA, Gao X, Gao W, Hu Z, Wang F, Qu Y, Zheng Y.   +6 more
europepmc   +1 more source

Reconsidering pancreatic masses: A case of IgG4-related autoimmune pancreatitis mimicking malignancy. [PDF]

Radiol Case Rep
Diani A, Benzalim M, Bouroumane MR, Alj S.   +3 more
europepmc   +1 more source

Fel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy

Allergy, Volume 81, Issue 6, Page 2156-2171, June 2026.
This study investigates the allergenicity and immunogenicity profile of a novel plant‐derived Fel d 1 bioparticle (eBP). Fel d 1 eBP promotes immune tolerance by redirecting allergic Th2 responses toward Th1 and IL‐10–producing regulatory pathways, including Bregs.
Janice A. Layhadi, Liliana Cifuentes Gutierrez, Sean T. Keane, William Fulton, Nichell A. Samson, Lily Y. D. Wu, Paulina Filipaviciute, Prista Hikmawati, Oleksandra Fedina, Ana Jimenez‐Gil, Stephen R. Durham, Guy Scadding, Guy Tropper, Louis‐Philippe Vézina, Patrick Colin, Ronald van Ree, Mohamed H. Shamji   +16 more
wiley   +1 more source

The Utility of IgG4/IgG Ratio in the Diagnosis of Multicentric Castleman Disease: A Case Report of HHV8+ Castleman Disease in a Patient with Classical Hodgkin's Lymphoma. [PDF]

Hematol Rep
Hagele A, Kay P, Nishino K, Mehta A, Liu Y, Nguyen AL, Lau E.   +6 more
europepmc   +1 more source

Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy

Allergy, Volume 81, Issue 6, Page 2172-2183, June 2026.
Rapid clinical relief of allergy symptoms during 18 months of sublingual immunotherapy (SLIT) for house dust mite (HDM) is associated with increased serum IgE, IgG2, and IgG4 to Der p 1 and Der p 2. Der p 1 and Der p 2 specific Type 2 memory B cells are expanded at 4 months and 12 months of SLIT, with increased expression of CD29 and IgG4.
Lin Hsin, Simone Reinwald, Anouk von Borstel, Pei Mun Aui, Kirsten Deckert, P. Mark Hogarth, Laurent Mascarell, Mark Hew, Robyn E. O'Hehir, Menno C. van Zelm   +9 more
wiley   +1 more source